Can Lynparza Hold On As PARP Inhibitors Enter First-Line Prostate Cancer Market?

 
• By Alaric DeArment
  
AZ Cambridge campus
AstraZeneca - along with Pfizer and J&J - presented Phase III PARP inhibitor data in first-line prostate cancer at ASCO GU • Source: Shutterstock

More from Anticancer

More from Therapy Areas